PENTASA- mesalamine capsule United States - English - NLM (National Library of Medicine)

pentasa- mesalamine capsule

avera mckennan hospital - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients who have demonstrated hypersensitivity to mesalamine, any other components of this medication, or salicylates.

MISOPROSTOL tablet United States - English - NLM (National Library of Medicine)

misoprostol tablet

avera mckennan hospital - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 200 ug - two 12-week, randomized, double-blind trials in osteoarthritic patients who had gastrointestinal symptoms but no ulcer on endoscopy while taking an nsaid compared the ability of 200 mcg of misoprostol tablets, 100 mcg of misoprostol tablets, and placebo to reduce the risk of gastric ulcer (gu) formation. patients were approximately equally divided between ibuprofen, piroxicam, and naproxen, and continued this treatment throughout the 12 weeks. the 200-mcg dose caused a marked, statistically significant reduction in gastric ulcers in both studies. the lower dose was somewhat less effective, with a significant result in only one of the studies. in these trials there were no significant differences between misoprostol tablets and placebo in relief of day or night abdominal pain. no effect of misoprostol tablets in reducing the risk of duodenal ulcers was demonstrated, but relatively few duodenal lesions were seen. in another clinical trial, 239 patients receiving aspirin 650 to 1300 mg q.i.d. for rheumatoid arth

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE capsule United States - English - NLM (National Library of Medicine)

chlordiazepoxide hydrochloride and clidinium bromide capsule

avera mckennan hospital - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - based on a review of this drug by the national academy of sciences — national research council and/or other information, fda has classified the indications as follows: "possibly" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. final classification of the less-than-effective indications requires further investigation. chlordiazepoxide hcl/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt disc

URSODIOL tablet, film coated United States - English - NLM (National Library of Medicine)

ursodiol tablet, film coated

avera mckennan hospital - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol 250 mg - ursodiol tablets, usp are indicated for the treatment of patients with primary biliary cirrhosis (pbc). patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation. pregnancy category b. reproduction studies have been performed in pregnant rats at oral doses up to 22 times the recommended maximum human dose (based on body surface area) and in pregnant rabbits at oral doses up to 7 times the recommended maximum human dose (based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to ursodiol. there are no adequate or well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. it is not known whether ursodiol is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ursodiol are administered to a nursing mothe

EDECRIN- ethacrynic acid tablet United States - English - NLM (National Library of Medicine)

edecrin- ethacrynic acid tablet

avera mckennan hospital - ethacrynic acid (unii: m5dp350vzv) (ethacrynic acid - unii:m5dp350vzv) - ethacrynic acid 25 mg - edecrin is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. all diuretics, including ethacrynic acid, are contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery diarrhea. if this occurs, it should be discontinued and not used again. until further experience in infants is accumulated, therapy with oral and parenteral edecrin is contraindicated. hypersensitivity to any component of this product.

HYDROCHLOROTHIAZIDE capsule United States - English - NLM (National Library of Medicine)

hydrochlorothiazide capsule

avera mckennan hospital - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide capsules are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ace inhibitors. usage in pregnancy : the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. dependent edema in pregnancy resulting from restriction of venous return by the expanded u

HYOSCYAMINE SULFATE tablet, orally disintegrating United States - English - NLM (National Library of Medicine)

hyoscyamine sulfate tablet, orally disintegrating

avera mckennan hospital - hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - hyoscyamine sulfate is indicated whenever antispasmodic or anticholinergic therapy is desired. the high degree of purity allows effective action at very low dosage, with a minimal incidence of unwanted side effects. may be contraindicated in glaucoma, prostatic hypertrophy and some cases of cardiac disease.

LORAZEPAM tablet United States - English - NLM (National Library of Medicine)

lorazepam tablet

avera mckennan hospital - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with -  hypersensitivity to benzodiazepines or to any components of the formulation. -  acute narrow-angle glaucoma.

HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet United States - English - NLM (National Library of Medicine)

hydrocodone bitartrate and acetaminophen tablet

directrx - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated, have not provided adequate analgesia, or are not expected to provide adequate analgesia hydrocodone bitartrate and acetaminophen tablets are contraindicated in patients with: significant respiratory depression [see warnings ] acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings] hypersensitivity to hydrocodone or a

CYCLOBENZAPRINE HYDROCHLORIDE tablet, film coated United States - English - NLM (National Library of Medicine)

cyclobenzaprine hydrochloride tablet, film coated

directrx - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride tablets, usp are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhibitors or withi